Influence of Fenofibrate Treatment on Triacylglycerides, Diacylglycerides and Fatty Acids in Fructose Fed Rats

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Sep 9

PMID 25198467

Citations 7

Authors

Thomas Kopf

Hans-Ludwig Schaefer

Martin Troetzmueller

Harald Koefeler

Mark Broenstrup

Tatiana Konovalova

Gerd Schmitz

Affiliations

Soon will be listed here.

Abstract

Fenofibrate (FF) lowers plasma triglycerides via PPARα activation. Here, we analyzed lipidomic changes upon FF treatment of fructose fed rats. Three groups with 6 animals each were defined as control, fructose-fed and fructose-fed/FF treated. Male Wistar Unilever Rats were subjected to 10% fructose-feeding for 20 days. On day 14, fenofibrate treatment (100 mg/kg p.o.) was initiated and maintained for 7 days. Lipid species in serum were analyzed using mass spectrometry (ESI-MS/MS; LC-FT-MS, GC-MS) on days 0, 14 and 20 in all three groups. In addition, lipid levels in liver and intestine were determined. Short-chain TAGs increased in serum and liver upon fructose-feeding, while almost all TAG-species decreased under FF treatment. Long-chain unsaturated DAG-levels (36:1, 36:2, 36:4, 38:3, 38:4, 38:5) increased upon FF treatment in rat liver and decreased in rat serum. FAs, especially short-chain FAs (12:0, 14:0, 16:0) increased during fructose-challenge. VLDL secretion increased upon fructose-feeding and together with FA-levels decreased to control levels during FF treatment. Fructose challenge of de novo fatty acid synthesis through fatty acid synthase (FAS) may enhance the release of FAs ≤ 16:0 chain length, a process reversed by FF-mediated PPARα-activation.

Citing Articles

Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease.

Fang Z, Shen G, Wang Y, Hong F, Tang X, Zeng Y Signal Transduct Target Ther. 2024; 9(1):66.

PMID: 38472195 PMC: 10933339. DOI: 10.1038/s41392-024-01781-9.

The Association Between Plasma Fatty Acid and Cognitive Function Mediated by Inflammation in Patients with Type 2 Diabetes Mellitus.

Shen J, Yu H, Li K, Ding B, Xiao R, Ma W Diabetes Metab Syndr Obes. 2022; 15:1423-1436.

PMID: 35573864 PMC: 9091472. DOI: 10.2147/DMSO.S353449.

Pemafibrate, A Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Reduces Plasma Eicosanoid Levels and Ameliorates Endothelial Dysfunction in Diabetic Mice.

Suto K, Fukuda D, Shinohara M, Ganbaatar B, Yagi S, Kusunose K J Atheroscler Thromb. 2021; 28(12):1349-1360.

PMID: 33775978 PMC: 8629704. DOI: 10.5551/jat.61101.

Fructose and hepatic insulin resistance.

Softic S, Stanhope K, Boucher J, Divanovic S, Lanaspa M, Johnson R Crit Rev Clin Lab Sci. 2020; 57(5):308-322.

PMID: 31935149 PMC: 7774304. DOI: 10.1080/10408363.2019.1711360.

Effect of fenofibrate on uric acid level in patients with gout.

Jung J, Choi Y, Suh C, Yoon D, Kim H Sci Rep. 2018; 8(1):16767.

PMID: 30425304 PMC: 6233215. DOI: 10.1038/s41598-018-35175-z.

References

Caldwell K . Field-flow fractionation. Anal Chem. 1988; 60(17):959A-971A. DOI: 10.1021/ac00168a001. View

Ledwith B, Pauley C, Wagner L, Rokos C, Alberts D, Manam S . Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells. J Biol Chem. 1997; 272(6):3707-14. DOI: 10.1074/jbc.272.6.3707. View

Panigrahy D, Kaipainen A, Huang S, Butterfield C, Barnes C, Fannon M . PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A. 2008; 105(3):985-90. PMC: 2242705. DOI: 10.1073/pnas.0711281105. View

Seo K, Kim K, Kim Y, Choi J, Lee K, Choi K . Comparison of oxidative stress and changes of xenobiotic metabolizing enzymes induced by phthalates in rats. Food Chem Toxicol. 2003; 42(1):107-14. DOI: 10.1016/j.fct.2003.08.010. View

OBrien M, Spear B, Glauert H . Role of oxidative stress in peroxisome proliferator-mediated carcinogenesis. Crit Rev Toxicol. 2005; 35(1):61-88. DOI: 10.1080/10408440590905957. View

Peters J, Cheung C, Gonzalez F . Peroxisome proliferator-activated receptor-alpha and liver cancer: where do we stand?. J Mol Med (Berl). 2005; 83(10):774-85. DOI: 10.1007/s00109-005-0678-9. View

Ueno T, Fukuda N, Nagase H, Tsunemi A, Tahira K, Matsumoto T . Atherogenic dyslipidemia and altered hepatic gene expression in SHRSP.Z-Leprfa/IzmDmcr rats. Int J Mol Med. 2009; 23(3):313-20. DOI: 10.3892/ijmm_00000133. View

Chirala S, Wakil S . Structure and function of animal fatty acid synthase. Lipids. 2005; 39(11):1045-53. DOI: 10.1007/s11745-004-1329-9. View

Ecker J, Scherer M, Schmitz G, Liebisch G . A rapid GC-MS method for quantification of positional and geometric isomers of fatty acid methyl esters. J Chromatogr B Analyt Technol Biomed Life Sci. 2012; 897:98-104. DOI: 10.1016/j.jchromb.2012.04.015. View

10.

Nishimura J, Dewa Y, Muguruma M, Kuroiwa Y, Yasuno H, Shima T . Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats. Toxicol Sci. 2007; 97(1):44-54. DOI: 10.1093/toxsci/kfm011. View

11.

Yu Y, Ginsberg H . The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann Med. 2004; 36(4):252-61. DOI: 10.1080/07853890410028429. View

12.

Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart J . Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998; 98(19):2088-93. DOI: 10.1161/01.cir.98.19.2088. View

13.

Yetukuri L, Huopaniemi I, Koivuniemi A, Maranghi M, Hiukka A, Nygren H . High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. PLoS One. 2011; 6(8):e23589. PMC: 3160907. DOI: 10.1371/journal.pone.0023589. View

14.

Vega G, Cater N, Hadizadeh 3rd D, Meguro S, Grundy S . Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome. Clin Pharmacol Ther. 2003; 74(3):236-44. DOI: 10.1016/S0009-9236(03)00170-X. View

15.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

16.

Ntambi J, Miyazaki M, Stoehr J, Lan H, Kendziorski C, Yandell B . Loss of stearoyl-CoA desaturase-1 function protects mice against adiposity. Proc Natl Acad Sci U S A. 2002; 99(17):11482-6. PMC: 123282. DOI: 10.1073/pnas.132384699. View

17.

Montanaro M, Rimoldi O, Igal R, Montenegro S, Tarres M, Martinez S . Hepatic delta9, delta6, and delta5 desaturations in non-insulin-dependent diabetes mellitus eSS rats. Lipids. 2003; 38(8):827-32. DOI: 10.1007/s11745-003-1132-7. View

18.

DOLE V, Meinertz H . Microdetermination of long-chain fatty acids in plasma and tissues. J Biol Chem. 1960; 235:2595-9. View

19.

Fauland A, Kofeler H, Trotzmuller M, Knopf A, Hartler J, Eberl A . A comprehensive method for lipid profiling by liquid chromatography-ion cyclotron resonance mass spectrometry. J Lipid Res. 2011; 52(12):2314-2322. PMC: 3220297. DOI: 10.1194/jlr.D016550. View

20.

Hartler J, Trotzmuller M, Chitraju C, Spener F, Kofeler H, Thallinger G . Lipid Data Analyzer: unattended identification and quantitation of lipids in LC-MS data. Bioinformatics. 2010; 27(4):572-7. DOI: 10.1093/bioinformatics/btq699. View